Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Saw palmetto GI adverse events could trigger NTP carcinogenicity, toxicity review.

This article was originally published in The Tan Sheet

Executive Summary

SAW PALMETTO GI ADVERSE REACTIONS MOST COMMON EVENT reported in a review of human data for the dietary supplement ingredient prepared by Integrated Laboratory Systems on behalf of the National Institute for Environmental Health Sciences. The report -- and two similar reviews of goldenseal and comfrey -- formed part of the basis for the National Toxicology Program Interagency Committee for Chemical Evaluation and Coordination recommendation that the three supplement ingredients and some of their respective constituents receive consideration for in vivo carcinogenicity and reproductive toxicity tests ("The Tan Sheet" Jan. 12, p. 13). The testing recommendations were published in the Jan. 8 Federal Register and are subject to a 60-day public comment period.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel